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Abstract
Despite the heightened awareness of diabetes as a major health problem, evidence on the impact of assistance and
organizational factors, as well as of adherence to recommended care guidelines, on morbidity and mortality in diabetes is
scanty. We identified diabetic residents in Torino, Italy, as of 1st January 2002, using multiple independent data sources. We
collected data on several laboratory tests and specialist medical examinations to compare primary versus specialty care
management of diabetes and the fulfillment of a quality-of-care indicator based on existing screening guidelines (GCI).
Then, we performed regression analyses to identify associations of these factors with mortality and cardiovascular morbidity
over a 4 year- follow-up. Patients with the lowest degree of quality of care (i.e. only cared for by primary care and with no
fulfillment of GCI) had worse RRs for all-cause (1.72 [95% CI 1.57–1.89]), cardiovascular (1.74 [95% CI 1.50–2.01]) and cancer
(1.35 [95% CI 1.14–1.61]) mortality, compared with those with the highest quality of care. They also showed increased RRs
for incidence of major cardiovascular events up to 2.03 (95% CI 1.26–3.28) for lower extremity amputations. Receiving
specialist care itself increased survival, but was far more effective when combined with the fulfillment of GCI. Throughout
the whole set of analysis, implementation of guidelines emerged as a strong modifier of prognosis. We conclude that
management of diabetic patients with a pathway based on both primary and specialist care is associated with a favorable
impact on all-cause mortality and CV incidence, provided that guidelines are implemented.
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Introduction
Because of its toll in terms of morbidity and mortality for
millions of people all over the world, diabetes is a major concern
for National Health Systems [1,2]. Recall of patients and processes
of screening such as hemoglobin A1c and lipid determination,
blood pressure measurement and annual eye and albuminuria
screening have proved to be effective in identifying and treating
patients at risk [3,4]. However, worldwide, the quality of care of
persons with diabetes, and intermediate or long-term outcomes of
the disease, are rather unsatisfactory and variable [5,6]. These
differences are influenced by a complex web of factors, in which
health care organization plays an important role. Unstructured
care in the community is associated with poorer follow up, greater
mortality and worse glycaemic control than hospital care. [7].
Organizational factors in diabetes care, in the long and medium
term, can greatly affect the prognosis of patients as regards survival
[8], morbidity and hospital utilization [9].
A surveillance population-based programme monitoring diabe-
tes through the employment of multiple data sources has been
implemented in the city of Torino, in north-western Italy.
Recently the programme has allowed to estimate the quality of
care process in terms of adherence to recommended guidelines
(GL) for monitoring of diabetes. On these premises the latter
survey revealed greater adherence to guidelines in patients cared
for by both specialist and primary care compared to those only
seen by General Practitioner (GP) [10].
Consequent to these previous findings, we investigated the
hypothesis that these differences in the type of care and adherence
to screening guidelines might have any impact on several hard
outcomes such as mortality and incidence of major cardiovascular
events.
Methods
Study population
The study base included residents in the city of Torino (900,000
inhabitants) at 1 January 2003, aged= 20 years, with a diagnosis of
diabetes. No ethical approval was requested according to Italian
law 211/2003 which explains that no ethic committee’s permission
is required for this kind of studies in Italy (anonymous aggregated
data). As described in detail elsewhere [11,12], patients were
identified using three data sources: the first source was the file of all
residents discharged from hospitals with a primary or secondary
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diagnosis of diabetes from January 1, 1997 to December 31, 2001.
The second data source was the file of prescriptions for anti-
diabetic drugs prescribed to residents from January 1 to December
31, 2001; we considered as persons with diabetes only those who
had at least two prescriptions of anti-diabetic drugs. The third
source was the file of all subjects who obtained exemption from
payment of drugs, syringes, and glucose monitoring strips due to a
diagnosis of diabetes from January 1, 1998 to December 31, 2001.
Figure 1. Source of ascertainment of people with diabetes and time windows used for exposure assessment and for follow-up.
doi:10.1371/journal.pone.0033839.g001
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All data sources were matched by a deterministic linkage
procedure using a unique identifier; the study population included
all persons who were present in at least one of three health data
sources (Figure 1). This database was further linked to the Torino
Population Register to include only people alive on 1 January,
2002 and to determine each individual’s educational level.
Treatment was classified into three groups: diet only, oral
antidiabetic drugs, and insulin. Information about therapy was
retrieved either from the RDR, or from prescriptions of
antidiabetic drugs. Subjects who were prescribed both insulin
and oral antidiabetic drugs were assigned to ‘‘insulin treatment’’;
all diabetic people who were not registered in the RDR and had
not received any antidiabetic drug prescription were considered
within the ‘‘diet only treatment’’ group. We considered all those
discharged from a hospital in the previous five years with a
diagnosis of coronary heart disease, cerebrovascular disease or
disease of arterie as individuals with established cardiovascular
disease (CVD).
The levels of care
All Italian citizens are cared for by a GP as part of the National
Health System (NHS). Specialist care for individuals with diabetes
is provided mainly by a public network of 700 diabetes clinics (14
in Torino), delivering diagnostic confirmation, therapy, counseling
on healthy life styles, and early diagnosis of complications, through
close patient follow-up by a diabetes team of professionals,
including diabetologists, and the scheduling of regular check-ups.
Most patients are referred to these care units by their GP and care
is free. All laboratory tests and specialist medical examinations
reimbursed by the NHS from 1 January 2002 to 31 december
2002 were linked to the population with diabetes (Figure 1).
Accordingly, we were able to identify the Guidelines Composite
Indicator (GCI), a measure which includes annual assessment of
A1C and at least two assessments from among eye examinations,
total serum cholesterol, and microalbuminuria. GCI can be
considered a proxy of fair adherence to screening guidelines (9).
We considered all individuals who had at least one consultation by
a diabetologist from 1 January 2002 to 31 december 2002 as cared
for by a diabetes center, whereas those who had not were
considered as cared for by a GP only, as 99.4% had at least one
contact with a GP in the same period. The study population was
classified according to four ‘‘levels of care’’: the ‘‘ONLY GP’’ level
(patients seen by GP but not at diabetes clinics and with no
fulfillment of GCI, i.e. poor adherence to GL), the ‘‘GP AND
SPECIALIST, WITHOUT GCI’’ level (patients seen by GP and
at diabetes clinics but with no fulfillment of GCI, i.e. poor
adherence to GL), the ‘‘GP AND GCI, WITHOUT SPECIAL-
IST’’ level (patients seen by GP and not at diabetes clinics but with
fulfillment of GCI, i.e. fair adherence to GL) and the ‘‘GP AND
SPECIALIST, WITH GCI’’ pathway (patients seen by GP and at
diabetes clinics and with fulfillment of GCI, i.e. fair adherence to
GL). We chose, as the reference group, the one with the highest
level of care, that is diabetes clinic plus adherence to guidelines,
because it is the standard care in the Region. Furthermore, it is the
same mode of analysis of a similar previous paper on quality of
process care [10].
Table 1. Characteristics of the study population Torino, 1 January 2003.
Level of care
A B C D Total
Characteristic Number (%)
All 6084 10997 1950 12073 31104
Gender Women 2957 (48.6) 5568 (50.6) 917 (47.0) 6133 (50.8) 15575 (50.1)
Men 3127 (51.4) 5429 (49.4) 1033 (53.0) 5940 (49.2) 15529 (49.3)
Age 21–44 215 (3.5) 385 (3.5) 111 (5.7) 744 (6.2) 1455 (4.7)
45–54 576 (9.5) 869 (7.9) 212 (10.9) 1088 (9.0) 2745 (8.8)
55–64 1785 (29.3) 2450 (22.3) 533 (27.3) 2433 (20.2) 7201 (23.2)
65–74 2428 (39.9) 3999 (36.4) 697 (35.7) 3519 (29.2) 10643 (34.2)
75–84 988 (16.2) 2739 (24.9) 365 (18.7) 3078 (25.5) 7170 (23.1)
.=85 92 (1.5) 555 (5.05) 32 (1.6) 1211 (10.0) 1890 (6.1)
Educational level High 669 (11.0) 1388 (12.6) 367 (18.8) 2138 (17.7) 4562 (14.7)
Average 1769 (29.1) 3044 (27.7) 624 (32.0) 3481 (28.8) 8918 (28.7)
Low 3646 (59.9) 6565 (59.7) 959 (49.2) 6454 (53.5) 17624 (56.7)
Treatment Diet 713 (11.7) 1318 (12.0) 246 (12.6) 3017 (25.0) 5294 (17.0)
Oral drugs 3656 (60.1) 6530 (59.4) 1205 (61.8) 7093 (58.8) 18484 (59.4)
Insulin 1715 (28.2) 3149 (28.6) 499 (25.6) 1963 (16.3) 7326 (23.6)
Cardiovascular disease Yes 942 (15.5) 2036 (18.5) 308 (15.8) 2526 (20.9) 5812 (18.7)
No 5142 (84.5) 8961 (81.5) 1642 (84.2) 9547 (79.1) 25292 (81.3)
GCI components A1C 6084 (100) 8226 (74.8) 1950 (100) 2912 (24.1) 19172 (61.6)
Total serum cholesterol 6026 (99.1) 6095 (55.4) 1909 (97.9) 3911 (32.4) 17941 (57.7)
Microalbuminuria 5091 (83.7) 437 (4.0) 1724 (88.4) 291 (2.4) 7543 (24.3)
Eye examination 2559 (42.1) 1906 (17.3) 810 (41.5) 808 (6.7) 6083 (19.6)
A=GP and Specialist, with GCI; B =GP and Specialist, without GCI; C =GP and GCI, without Specialist; D =Only GP.
doi:10.1371/journal.pone.0033839.t001
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Outcomes
Subjects were followed up for mortality, incidence of acute
myocardial infarction (AMI) and stroke, and non-traumatic lower
extremity amputations (LEA). Information on causes of death,
from the local mortality registries, was classified according to the
International Classification of Diseases, 9th Revision (ICD-9):
cardiovascular disease (390–459), coronary heart disease (CHD;
410–414), cerebrovascular disease (stroke; 430–438), and cancer
(140–208).
AMI incident cases were identified through hospital and causes-
of death-registries [13]. Hospital discharges with ICD9-CM code
410* as primary discharge diagnosis, or as secondary diagnosis
when associated with selected codes suggestive of ischemic
symptoms in primary diagnosis, and deaths with the ICD9 code
410* as underlying cause were selected. Individuals without a
previous hospitalization for ICD9-CM codes 410* or 412* during
the previous 60 months were considered as incident cases [12,14].
Acute stroke incident cases were identified through hospital and
causes-of-death registries [13]. Hospital discharges with ICD9-CM
codes 430*, 431*, 434*, and 436* as primary discharge diagnosis,
excluding patients with 438* code in secondary diagnosis, and
deaths with ICD9 codes 430*, 431*, 434*, and 436* as underlying
cause were selected. Individuals without a previous hospitalization
for stroke diagnosis during the previous 60 months were
considered as incident cases [12,14].
LEA were identified using hospital discharges records with a
DRG code of 113, 114, or 285. We considered the first discharge
for each subject in the period 2003–2006.
Statistical analysis
The start of follow-up was defined as January 1, 2003, excluding
all persons who died or moved out of Turin in 2002, and ended at
the date of incidence, death, transfer out of the area of residence,
or December, 31, 2006. We considered as lost to follow-up people
who moved out of Turin during the study period (4.3%) (Figure 1).
Days of follow-up were calculated as the difference between
January 1, 2003, and the date of the event under study, loss to
follow-up, death (if incidence was under study) or December 31,
2006, where appropriate. Person-time was calculated separately
for each event; for example, when AMI incidence was studied,
days of follow up were calculated until the occurrence of first AMI,
and, in case a stroke occurred before AMI, the former was not
considered (i.e. observation was not censored because of the
stroke). Mortality/incident rates were calculated by dividing the
number of death/incident cases by the total person-time and
expressed in terms of event per 1,000 person-years. Both mortality
and incidence density were standardized on the age distribution of
the 2008 local population (5-years age classes, from 20–24 to
.84). Cumulative survival probabilities according to pathways of
care were estimated with the Kaplan-Meier method and
compared using the log-rank test. Poisson regression was used to
estimate, by each levels of care, adjusted rate ratios (RR) for
available potential predictors of death or incidence: age (21–44;
45–54; 55–64; 65–74; 75–84; .84 years), gender, educational
level, treatment (insulin, oral antidiabetic treatment, diet only),
previous history of CVD, and Local Health Unit of residence (4 in
Turin). The statistical analyses were conducted using the SAS
System, version 9.1.
Results
We identified 31104 persons with diabetes ($20 years) resident
in Torino on 1 January 2003, whose diagnosis of diabetes was
already confirmed on 1 January 2002. Baseline characteristics of
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Figure 2. Kaplan Meier survival curves of different mortality causes.
doi:10.1371/journal.pone.0033839.g002
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the study population according to the levels of care are shown in
table 1. Less than 20% of patients were seen both by a diabetes
clinic and received a screening for complications, while more than
one third of patients diabetes clinic’s consultation did not result in
a basic screening for complications (GP AND SPECIALIST,
WITHOUT GCI group). About 40% of patients were not cared
appropriately, as they were neither seen by a diabetes clinic, nor
appropriately screened for complications, while 6% were appro-
priately cared by a GP without consultation from a diabetologist.
Persons cared with poor adherence to GL (ONLY GP group) were
more likely to be old, with no pharmacological treatment and with
cardiovascular disease, while patients belonging to the three other
groups showed only slight socio-demographic and clinical
differences.
During 4-year follow-up all cause mortality was 46.7 per 1,000
person-years (18.2 from cardiovascular disease), AMI, stroke and
LEA incidence were, respectively, 10.8, 9.4 and 1.5 per 1,000
person-years. Both all cause and cardiovascular age-adjusted
mortality were higher in the ONLY GP group compared to other
pathway of care, but differences were less evident when compared
to the GP AND SPECIALIST, WITHOUT GCI group. A slight
difference in this pattern was found in cancer mortality with the
GP, WITHOUT SPECIALIST AND GCI group characterized
by the lowest rate. As for incidence, differences between levels of
care were less marked, even if the GP AND SPECIALIST, WITH
GCI group almost constantly showed the lowest risks (table 2).
Unadjusted Kaplan-Meier curves showed that the GP AND
SPECIALIST, WITH GCI (and GP, WITHOUT SPECILAL-
IST AND GCI) level was associated with a significant (p,0.0001)
lower likelihood of mortality, both from all-causes and from
cardiovascular disease and cancer (figure 2).
Table 3 shows the RRs for the outcomes considered, adjusted
for age, gender, educational level, Local Health Unit of residence,
cardiovascular disease and treatment. All of them showed a very
similar pattern: worse outcomes in the ONLY GP group,
intermediate in the GP AND GCI, WITHOUT SPECIALIST
group whereas the best outcomes could be found in the GP AND
SPECIALIST, WITH GCI group. Interestingly, diabetologist’s
consultation added little to adherence to guidelines, since the RR
of the small GP AND GCI, WITHOUT SPECIALIST group is
not significantly different from that of the GP AND SPECIALIS,
WITH GCI group. With respect of mortality, a consistent added
value of diabetologist consultation, independent of guidelines
implementation, stood out in the comparison between the GP
AND SPECIALIST, WITHOUT GCI and the ONLY GP
groups.
Discussion
The main finding of our study is the link between some
assistance and organizational factors (type and quality of
assistance) and hard outcomes of diabetes. Compared with those
followed with the highest quality of care, patients who had been
managed in an old-fashion, unstructured way (i.e. no planned
screening and no diabetes clinic referrals), had excess all-cause
mortality (RR 1.72), and excess incidence of cardiovascular events
(RRs for AMI 1.31, for stroke 1.32 and for LEA 2.03). These
trends are consistent throughout the outcomes considered:
mortality appeared to be increased not only for cardiovascular
diseases, but also for cancer; incidence of major cardiovascular
events, consistently increased for myocardial infarction, stroke and
amputation, mirrors the pattern of mortality, even if at a lower
scale. While the relation between diabetes and cardiovascular
disease has been well known for long time, nowadays also the link
between diabetes and cancer is established to such an extent, that
cancer can be viewed as a new chapter in the field of diabetes
complications [15]. Also in this population the risk of death from
cancer for people with diabetes, compared with those without
diabetes, was increased of 40% in both genders [13]. Moreover,
there appear to be a protective effect of aggressive diabetes
treatment on cancer development: previous observations in the
Verona Study [8] had suggested lower cancer mortality in
diabetics on diet seen at diabetes clinics (Verlato, personal
communication) and metformin has been shown to have a
protective effect on tumors occurrence [16]. In our study the
protective effect of diabetes clinic consultation is confirmed in
addition to a novel piece of news, i.e. this result is even more
apparent when there is a good implementation of GL. Besides
metformin use, lifestyle modifications, that are usually suggested
and enforced in more structured models of care as a tool for better
metabolic control and CV prevention, and/or the routine
periodical encounter and interview with a doctor, may be
responsible for this finding.
Consistently with other studies, diabetes clinic referral
[8,11,17,18] emerges as a good predictor of better long-term
Table 3. Rates ratios (RR) and 95% confidence intervals for mortality and for incidence of major cardiovascular events by level of
care; 2003–2006.
Level of care
Specialist and GP,
with GCI
Specialist and GP, without
GCI
GP and GCI, without
Specialist Only GP
RR RR (95% CI) RR (95% CI) RR (95% CI)
Mortality All causes 1 1.29 (1.17–1.41) 0.95 (0.81–1.12) 1.72 (1.57–1.89)
Cardiovascular disease 1 1.19 (1.03–1.38) 1.06 (0.82–1.37) 1.74 (1.50–.2.01)
CHD 1 1.16 (0.93–1.46) 1.31 (0.91–1.88) 1.48 (1.18–1.86)
Stroke 1.04 (0.76–1.40) 0.77 (0.43–1.38) 1.93 (1.44–2.57)
Cancer 1 1.26 (1.07–1.50) 0.86 (0.63–1.17) 1.35 (1.14–1.61)
Incidence AMI 1 1.24 (1.04–1.47) 1.22 (0.92–1.60) 1.31 (1.10–1.55)
Stroke 1 1.14 (0.95–1.38) 0.77 (0.54–1.09) 1.32 (1.09–1.59)
LEA 1 1.57 (0.99–2.50) 1.15 (0.51–2.56) 2.03 (1.26–3.28)
doi:10.1371/journal.pone.0033839.t003
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prognosis, being itself associated with a reduction of the
probability of death by more than 33%. Compared with those
who are only cared for by other physicians, patients seen at a
diabetes center are more likely to be monitored according to
guidelines, regardless of severity-of-disease effect [10], and to
receive structured education as well as more aggressive treatment
when needed [19]. In our results this property is still retained by
diabetologists, but it is dampened when the consultation does not
result in a sufficient adherence to guidelines. From the point of
view of the care system this is valuable, new information.
The impact of GLs implementation in diabetes management on
hard outcomes such as death and incidence of chronic
complications is still controversial. De Belvis et al. have found
that adherence to EBM instruments is likely to improve process of
care, rather than patient outcomes [20]. Other authors [21] have
evaluated the effect of GLs on intermediate or process indicators
concluding that a quality improvement program improved the
provision of diabetes care but was not accompanied by any effect
on patient outcomes. When it comes to hard end points, such as
mortality or incidence of CVD, particularly for short periods of
time, the available evidence becomes weak. Recently, several
investigations have explored the impact of GLs on morbidity: a
favorable impact of GL on development of macrovascular
complications [22] and a positive relationship between good
performance of doctors in process indicators and reduction of
cardiovascular events over time have been described [23]. Both
suggest some evidence in favor of adherence to guidelines, but
these surveys refer either to patients cared for by diabetes clinics or
to selected cohorts, and not to the general population of
individuals with diabetes. A strength of our study is that, through
record linkage between several data sources, we were able to
accurately monitor the care process and outcomes longitudinally
at the population level. Throughout all the analysis of the Torino
Study, adherence to GLs emerged as a strong modifier of
prognosis in the diabetic population of the city, therefore, to the
best of our knowledge, this is the first confirmation that the link
between diabetes clinic referral and adherence to GLs in a large
unselected population with diabetes has favorable impact on
mortality. Finally, we hold that the findings of this study can be
generalised to other health system as the protective effect over
adverse health outcomes of adherence to guide lines is not
dependent on the heath system. Moreover, diabetologists and
diabetes clinics exist in all developed nations. Referring patients to
diabetes clinics for diabetes may be easier in some countries but it
is possible in most of health systems.
Our study has limitations that could affect the results. Available
administrative databases neither provide information on clinical
features of the disease (type of diabetes, age of onset, duration of
the disease) nor whether risk control targets have been met and the
GCI is an indicator only based on screening guidelines, nor on
treatment recommendations. However, better quality of the
process of care often translates into better performance as regards
attainment of treatment goals [24], and the final hard outcomes
considered, death and CV incidence, enabled us to look at the
result beyond any reasonable doubt. Second, the way we classified
the levels of care could have introduced some differential
misclassification; persons severely ill for conditions other than
diabetes (as persons with end stage chronic diseases) are more
likely to be poorly cared according to diabetes GLs and thus
included in the ONLY GP model of care. This could explain, at
least in part, the high mortality rates in this group, and the less
steep difference in incidence; given the administrative nature of
our data set we were only able to adjust for diagnosed
cardiovascular diseases, but not for other severe clinical conditions,
so residual confounding could explain our results. However, the
presence of a strong bias should result in a steeper mortality in the
first months of the follow up in the ONLY GP group, while
survival curve in the ONLY GP group shows a regular slope
during the whole 4 years of follow-up; moreover, differential
misclassification unlikely affects the other three levels. Self-
motivation, and willingness to be treated and followed up, could
be possible indication bias leading to the best outcomes of the GP
AND SPECIALIST, WITH GCI group. In other words, patients
who are more spontaneously prone to adhere to the best
management of diabetes could have benefited from this predispo-
sition, regardless of the type of care. In this regards a counterpoint
is that the adjustment for education level, which is a known proxy
of spontaneously adherence to better care [25], could have limited
this interference.
A reasonable conclusion is that these findings suggest that a
shared care based on both patient management by diabetes clinic
and GP in a joint way, has some advantage in treating diabetes
and, probably, chronic illnesses. GPs are not accustomed to active
medicine and still perform a sort of ‘‘on demand‘‘ medicine with
no structured recall [26], a particularly effective tool in chronic
illness and diabetes [6]; on the other hand specialists are more at
ease with education, with periodical recall and start earlier
effective therapies [10,19]. Shared pathways assessing ‘‘who does
what’’ at any time of the course of the disease could be valuable
tools to plan effective population-based intervention on diabetes.
Finally, as attending diabetes clinics alone without GL-screening
results in worse health outcomes, more efforts to promote GLs
adherence among GPs and diabetologists alike are needed.
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